EMA Endorses Dexamethasone For COVID-19
The Move Should Speed Up EU National Approvals
Companies marketing dexamethasone in Europe have been told they can use a CHMP endorsement to request the addition of COVID-19 to their product license.
You may also be interested in...
World Health Organization recommendations to use dexamethasone and hydrocortisone to treat patients with severe and critical COVID-19 demonstrate the potential for common and low-cost generics in fighting the coronavirus pandemic.
The European Medicines Agency has started reviewing under its fast-track pathway an application to market Dexamethasone Taw as a treatment for hospitalized patients with COVID-19.
Positive trial results for dexamethasone in treating COVID-19 patients demonstrate the potential of repurposing existing generic medicines to fight the coronavirus pandemic.